Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Novel Immune-related Long Noncoding Rna (lncrna) Pair Model To Predict The Prognosis Of Triple-negative Breast Cancer.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Novel Immune-related Long Noncoding Rna (lncrna) Pair Model To Predict The Prognosis Of Triple-negative Breast Cancer.

Related Experiment Video

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

A novel immune-related long noncoding RNA (lncRNA) pair model to predict the prognosis of triple-negative breast cancer.

Jing-Ying Li1, Chen-Ji Hu1, Hui Peng1

  • 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.

Translational Cancer Research
|April 15, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

This study developed a novel risk model using immune-related long noncoding RNA pairs to predict immunotherapy effectiveness in metastatic triple-negative breast cancer (TNBC). The lncRNA USP30-AS1 shows potential as a therapeutic target for TNBC by correlating with PD-L1 expression.

Keywords:
Breast cancer (BC)The Cancer Genome Atlas (TCGA)immune-related long noncoding RNAs (irlncRNAs)triple-negative breast cancer (TNBC)

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.0K

Related Experiment Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.0K

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Breast cancer (BC) is a leading cause of cancer death in women.
  • Anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) immunotherapy shows promise in metastatic triple-negative breast cancer (TNBC).
  • Immune-related long noncoding RNAs (irlncRNAs) may influence PD-1/PD-L1 pathway efficacy in cancer immune escape.

Purpose of the Study:

  • To explore the regulatory mechanisms of irlncRNAs in PD-1/PD-L1 immunotherapy for TNBC.
  • To develop a predictive model for immunotherapy efficacy in TNBC patients.
  • To identify specific irlncRNAs associated with immune responses and PD-L1 expression.

Main Methods:

  • Transcriptome profiling data from The Cancer Genome Atlas (TCGA) was analyzed.
  • Differentially expressed irlncRNA (DEirlncRNA) pairs were identified.
  • A risk assessment model was constructed using Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis.

    • Main Results:

    • The developed risk model demonstrated potential as a predictive tool for TNBC patients, validated by ROC curve analysis.
    • Clinical stage and risk score were identified as independent prognostic predictors.
    • The lncRNA USP30-AS1 was identified and found to be positively correlated with PD-L1 expression and associated with immune responses.

    Conclusions:

    • A novel risk assessment model based on irlncRNA pairs can predict immunotherapy efficacy in TNBC.
    • The lncRNA USP30-AS1 is a potential therapeutic target for TNBC, linked to PD-L1 expression and immune responses.